Filtered By:
Condition: Thrombosis
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 687 results found since Jan 2013.
General recommendations for the management of glomerular diseases-2023
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):696-704. doi: 10.1007/s00508-023-02265-6. Epub 2023 Sep 20.ABSTRACTGlomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreove...
Source: Wiener Klinische Wochenschrift - September 20, 2023 Category: General Medicine Authors: Martin Windpessl Philipp Gauckler Emanuel Zitt Karl Lhotta Cihan Ay Kathrin Eller Balazs Odler Irmgard Neumann Michael Rudnicki Andreas Kronbichler Marcus D S äemann Source Type: research
Autoantibodies enhance ADAMTS13 clearance in patients with immune thrombotic thrombocytopenic purpura
CONCLUSIONS: These data reveal, both at presentation and during PEX treatment, that antibody-mediated clearance of ADAMTS13 is the major pathogenic mechanism causing ADAMTS13 deficiency in iTTP. Understanding the kinetics of ADAMTS13 clearance in iTTP may now enable further optimisation of iTTP patient treatment.PMID:36813118 | DOI:10.1016/j.jtha.2023.02.011
Source: Thrombosis and Haemostasis - February 22, 2023 Category: Hematology Authors: Mary I Underwood Ferras Alwan Mari R Thomas Marie A Scully James Tb Crawley Source Type: research
Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study
CONCLUSION: A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.PMID:36186101 | PMC:PMC9483174 | DOI:10.1002/rth2.12792
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Adam Rosenberg Catelyn Cashion Fariya Ali Harini Haran Raaj K Biswas Vivien Chen Helen Crowther Jennifer Curnow Elyssa Deakin Chee-Wee Tan Yi Ling Tan Andrew Vanlint Christopher M Ward Robert Bird David J Rabbolini Source Type: research
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research
Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research
Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research
Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research
Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research
The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome
Lupus. 2022 Sep 8:9612033221122147. doi: 10.1177/09612033221122147. Online ahead of print.ABSTRACTLimited evidence exists to guide the management of recurrent thrombosis occurring despite therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In this case series, fondaparinux, with or without an antiplatelet agent, provided an effective and safe option in three patients with thrombotic APS, all two triple and one single positive for antiphospholipid antibodies, who had recurrent venous and/or arterial thromboembolism. Rituximab was also used in all patients. Recurrent events occurred despi...
Source: Lupus - September 8, 2022 Category: Rheumatology Authors: Zara Sayar Shoshana Burke Prabal Mittal Hannah Cohen Source Type: research
